ZEB1 and breast carcinoma: The capacity of CRISPR to induce ZEB1 repression was assessed in two human TNBC cell lines, SUM159 and MDA‐MB‐231, representing models for the claudin‐low mesenchymal subtype of breast cancer.[59]